Vir Bio Narrows Q3 Loss to $163M Amid Revenue Dip, R&D Cuts

Ticker: VIR · Form: 10-Q · Filed: 2025-11-05T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Clinical Stage, Net Loss, R&D Expenses, Cash Burn, Infectious Diseases, Oncology

Related Tickers: VIR

TL;DR

**Vir Bio is still bleeding cash, but less so, as revenue tanks and R&D tightens; a high-risk bet on pipeline success.**

AI Summary

Vir Biotechnology, Inc. reported a significant net loss of $163.1 million for the three months ended September 30, 2025, an improvement from the $213.7 million net loss in the same period of 2024. Total revenues decreased substantially to $0.24 million for the three months ended September 30, 2025, down from $2.38 million in the prior year, primarily due to a reduction in contract and grant revenue. Research and development expenses also saw a decrease, falling to $151.5 million from $195.2 million year-over-year, reflecting a strategic shift in program focus. The company's cash, cash equivalents, and investments stood at $810.7 million as of September 30, 2025, which management believes is sufficient to fund operations for at least the next twelve months. Despite the reduced burn rate, the accumulated deficit grew to $1.15 billion by September 30, 2025, from $759.8 million at December 31, 2024, indicating continued significant losses. The company is focused on its clinical-stage portfolio, including programs for chronic hepatitis delta and dual-masked T-cell engagers, and has exclusive rights to the PRO-XTEN masking platform.

Why It Matters

For investors, Vir Biotechnology's continued substantial net losses and declining revenue, despite reduced R&D spending, signal ongoing challenges in commercializing its pipeline. The company's reliance on its $810.7 million cash reserves for future operations, while deemed sufficient for 12 months, highlights the critical need for clinical success and potential new revenue streams. Employees face a dynamic environment as the company refines its focus on specific clinical programs like chronic hepatitis delta and T-cell engagers. Customers and the broader market will be impacted by the success or failure of these programs, particularly in infectious diseases and oncology, where effective treatments are highly sought after. The competitive landscape in biopharmaceuticals demands rapid innovation and successful clinical trials, putting pressure on Vir Bio to deliver tangible results from its PRO-XTEN platform.

Risk Assessment

Risk Level: high — Vir Biotechnology reported a net loss of $163.1 million for the three months ended September 30, 2025, and an accumulated deficit of $1.15 billion, indicating significant ongoing financial losses. Total revenues plummeted from $2.38 million in Q3 2024 to $0.24 million in Q3 2025, a 90% decrease, highlighting a lack of substantial commercial products. The company's liquidity, while stated as sufficient for 12 months with $810.7 million in cash and investments, is being rapidly consumed by operating activities, with net cash used in operating activities at $365.9 million for the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and closely monitor Vir Biotechnology's clinical trial progress and any potential new collaboration agreements. Given the substantial net losses and declining revenue, new investments should be considered highly speculative, contingent on significant positive data readouts from their hepatitis delta or T-cell engager programs.

Financial Highlights

debt To Equity
0.28
revenue
$0.24M
operating Margin
-86721.5%
total Assets
$1,019.45M
total Debt
$223.36M
net Income
-$163.1M
eps
-$1.17
gross Margin
N/A
cash Position
$810.7M
revenue Growth
-89.9%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration revenue-$0.65M-68.3%
Contract revenue$3.39M-93.8%
Grant revenue$1.73M-81.6%

Key Numbers

Key Players & Entities

FAQ

What were Vir Biotechnology's total revenues for the three months ended September 30, 2025?

Vir Biotechnology's total revenues for the three months ended September 30, 2025, were $0.24 million, a significant decrease from $2.38 million reported in the same period of 2024.

How much cash and investments did Vir Biotechnology have as of September 30, 2025?

As of September 30, 2025, Vir Biotechnology had $810.7 million in cash, cash equivalents, and investments, which management believes is sufficient to fund operations for at least twelve months.

What was Vir Biotechnology's net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Vir Biotechnology reported a net loss of $395.064 million, compared to a net loss of $417.371 million for the same period in 2024.

Did Vir Biotechnology's research and development expenses change year-over-year?

Yes, Vir Biotechnology's research and development expenses decreased to $151.463 million for the three months ended September 30, 2025, from $195.178 million in the comparable period of 2024.

What is Vir Biotechnology's primary business focus?

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer, with a portfolio including programs for chronic hepatitis delta and dual-masked T-cell engagers.

What is the significance of the PRO-XTEN masking platform for Vir Biotechnology?

Vir Biotechnology has exclusive rights to the PRO-XTEN masking platform for oncology and infectious disease, which is a key technology in its preclinical and clinical development efforts.

How has Vir Biotechnology's accumulated deficit changed?

Vir Biotechnology's accumulated deficit increased to $1.154 billion as of September 30, 2025, from $759.784 million as of December 31, 2024, reflecting continued operational losses.

What is the company's outlook on its liquidity?

As of September 30, 2025, the company had $810.7 million in cash, cash equivalents, and investments, which it believes would be sufficient to fund its operations for at least twelve months from the issuance date of these financial statements.

Are there any ongoing legal proceedings for Vir Biotechnology?

The 10-Q filing indicates that information regarding legal proceedings is covered under Part II, Item 1, but no specific details are provided in the excerpt.

What was the net cash used in operating activities for Vir Biotechnology for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Vir Biotechnology used $365.905 million in net cash from operating activities, compared to $358.717 million in the same period of 2024.

Risk Factors

Industry Context

Vir Biotechnology operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing treatments for serious diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Recent trends include a focus on novel therapeutic modalities, strategic partnerships, and consolidation, driven by the pursuit of breakthrough treatments and the need to share development risks and costs.

Regulatory Implications

As a clinical-stage biotechnology company, Vir Biotechnology is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety endpoints, or changes in regulatory pathways can significantly impact product development timelines and market access. Compliance with evolving regulations is critical for advancing its pipeline and achieving commercialization.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total losses that have not been offset by profits. (Indicates the company's history of unprofitability, with a significant increase to $1.15 billion by September 30, 2025.)
Collaboration revenue
Revenue generated from agreements with other companies where research, development, or commercialization efforts are shared. (This revenue stream has significantly declined, contributing to the overall revenue decrease.)
Contract revenue
Revenue earned from specific contractual agreements, often for services or milestones achieved. (A major component of the revenue decline, indicating fewer active contracts or lower value from existing ones.)
Grant revenue
Income received from government agencies or foundations to support research and development activities. (Another significant contributor to the overall revenue decrease, suggesting reduced funding from these sources.)
Research and development expenses
Costs incurred in the process of discovering, developing, and testing new products or technologies. (While reduced, these expenses remain high, reflecting the company's ongoing investment in its pipeline.)
Cash, cash equivalents, and investments
Highly liquid assets that can be readily converted to cash, including money market funds and short-term marketable securities. (Represents the company's liquidity, which management believes is sufficient for at least 12 months of operations.)
Operating lease right-of-use assets
An asset recognized under lease accounting standards representing the right to use an underlying asset for the lease term. (These assets, along with corresponding liabilities, reflect the company's long-term commitments for leased facilities or equipment.)
Contingent consideration obligation
A potential future payment obligation that depends on the achievement of certain milestones or events, often related to acquisitions or licensing deals. (Represents potential future cash outflows that could impact liquidity if triggered.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Vir Biotechnology has experienced a significant downturn in revenue, with total revenues dropping from $2.38 million in Q3 2024 to $0.24 million in Q3 2025, a decrease of nearly 90%. While operating expenses, particularly R&D, have been reduced, the company continues to incur substantial net losses, with the Q3 2025 loss of $163.1 million being an improvement from $213.7 million in Q3 2024. The accumulated deficit has grown substantially, indicating ongoing profitability challenges. New risks related to the company's strategic program focus and the inherent uncertainties of clinical development are now more prominent.

Filing Stats: 4,452 words · 18 min read · ~15 pages · Grade level 18.9 · Accepted 2025-11-05 17:15:30

Key Financial Figures

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (unaudited) 3 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 65 Item 3. Defaults Upon Senior Securities 65 Item 4. Mine Safety Disclosures 65 Item 5. Other Information 65 Item 6. Exhibits 66

Signatures

Signatures 67 1 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development, potential of, and expectations for, our pipeline and technology platforms, the timing, potential of and expectations for ongoing and planned preclinical and clinical studies, the timing and likelihood of regulatory filings and potential approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations and in-licensing arrangements, projected costs, prospects, plans, objectives of management, expected market size and growth for our potential products, the timing of availability of clinical data, program updates and data disclosures, and our plans for our portfolio, including our hepatitis delta virus and masked T-cell engager portfolios, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "might", "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. VIR BIOTECHNOLOGY, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) September 30, 2025 December 31, 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 170,084 $ 222,947 Short-term investments 327,750 678,051 Restricted cash and cash equivalents, current 2,215 89,385 Equity investments 8,679 4,350 Prepaid expenses and other current assets 36,956 47,725 Total current assets 545,684 1,042,458 Intangible assets, net 7,924 8,120 Goodwill 16,937 16,937 Property and equipment, net 58,203 63,183 Operating lease right-of-use assets 63,555 59,680 Restricted cash and cash equivalents, noncurrent 6,957 6,363 Long-term investments 304,212 190,015 Other assets 15,981 12,057 TOTAL ASSETS $ 1,019,453 $ 1,398,813 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 6,847 $ 5,081 Accrued and other liabilities 68,375 85,873 Deferred revenue, current — 12,648 Contingent consideration obligation, current — 16,060 Total current liabilities 75,222 119,662 Deferred revenue, noncurrent 9,433 — Operating lease liabilities, noncurrent 91,215 90,139 Contingent consideration obligation, noncurrent 34,180 24,050 Other long-term liabilities 13,305 14,577 TOTAL LIABILITIES 223,355 248,428 Commitments and contingencies (Note 7) STOCKHOLDERS' EQUITY: Preferred stock, $ 0.0001 par value; 10,000,000 shares authorized as of September 30, 2025 and December 31, 2024; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 300,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 139,022,594 and 136,959,446 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 14 14 Additional paid-in capital 1,952,843 1,911,872 Accumulated other comprehensive loss ( 1,911 ) ( 1,717 ) Accumulated deficit ( 1,154,848 ) ( 759,784 ) TOTAL STOCKHOLDERS'

View on Read The Filing